(Total Views: 78)
Posted On: 12/05/2024 2:06:00 PM
Post# of 25471

$DYAI Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology https://finance.yahoo.com/news/dyadic-receive...00271.html

